GlobeNewswire: Chembio Diagnostics, Inc. Contains the last 10 of 280 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T22:30:04ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2023/04/27/2656944/0/en/Biosynex-Completes-Acquisition-of-Chembio-Diagnostics-Inc.html?f=22&fvtc=4&fvtv=15990Biosynex Completes Acquisition of Chembio Diagnostics, Inc.2023-04-27T20:30:00Z<![CDATA[Chembio Diagnostics, Inc. becomes the first North American structure controlled by Biosynex in North America]]>https://www.globenewswire.com/news-release/2023/04/19/2649954/0/en/Chembio-Stockholders-Urged-to-Tender-Shares-Before-6-00-P-M-New-York-City-Time-on-April-26-2023.html?f=22&fvtc=4&fvtv=15990Chembio Stockholders Urged to Tender Shares Before 6:00 P.M., New York City Time, on April 26, 20232023-04-19T12:00:00Z<![CDATA[Failure to tender shares could result in the termination of the proposed merger between Chembio and Biosynex Failure to tender shares could result in the termination of the proposed merger between Chembio and Biosynex]]>https://www.globenewswire.com/news-release/2023/04/13/2646048/0/en/Biosynex-Extends-Tender-Offer-for-the-shares-of-Chembio-Diagnostics-Inc.html?f=22&fvtc=4&fvtv=15990Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.2023-04-13T11:00:00Z<![CDATA[STRASBOURG, France, April 13, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, today announced that Project Merci Merger Sub, Inc. (“Purchaser”), a Nevada corporation and its wholly-owned indirect subsidiary, has extended the expiration time for the previously announced tender offer to purchase all of the issued and outstanding shares of common stock (the “Shares”) of Chembio Diagnostics, Inc. (Nasdaq: CEMI) (“Chembio”) at a price of $0.45 per Share, net to the seller in cash, without interest and subject to any required tax withholding, until 6:00 p.m., New York City time on April 26, 2023, unless further extended. The tender offer was previously scheduled to expire at 6:00 p.m., New York City time, on April 12, 2023. All other terms and conditions of the tender offer remain unchanged.]]>https://www.globenewswire.com/news-release/2023/04/10/2643602/0/en/Chembio-Stockholders-Reminded-to-Tender-Shares-Before-6-00-P-M-New-York-City-Time-on-April-12-2023.html?f=22&fvtc=4&fvtv=15990Chembio Stockholders Reminded to Tender Shares Before 6:00 P.M., New York City Time, on April 12, 20232023-04-10T12:00:00Z<![CDATA[MEDFORD, N.Y., April 10, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders concerning the pending tender offer by Biosynex SA.]]>https://www.globenewswire.com/news-release/2023/04/03/2640165/0/en/Chembio-s-CEO-Letter-to-Stockholders.html?f=22&fvtc=4&fvtv=15990Chembio’s CEO Letter to Stockholders2023-04-03T20:15:00Z<![CDATA[Reminder to Tender Shares Before 6:00 P.M., New York City Time, on April 12, 2023 Reminder to Tender Shares Before 6:00 P.M., New York City Time, on April 12, 2023]]>https://www.globenewswire.com/news-release/2023/03/29/2636522/0/en/Biosynex-Extends-Tender-Offer-for-the-shares-of-Chembio-Diagnostics-Inc.html?f=22&fvtc=4&fvtv=15990Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.2023-03-29T11:00:00Z<![CDATA[STRASBOURG, France, March 29, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, today announced that Project Merci Merger Sub, Inc. (“Purchaser”), a Nevada corporation and its wholly-owned indirect subsidiary, has extended the expiration time for the previously announced tender offer to purchase all of the issued and outstanding shares of common stock (the “Shares”) of Chembio Diagnostics, Inc. (Nasdaq: CEMI) (“Chembio”) at a price of $0.45 per Share, net to the seller in cash, without interest and subject to any required tax withholding, until 6:00 p.m., New York City time on April 12, 2023, unless further extended. The tender offer was previously scheduled to expire at 6:00 p.m., New York City time, on March 28, 2023. All other terms and conditions of the tender offer remain unchanged.]]>https://www.globenewswire.com/news-release/2023/03/21/2631126/0/en/Chembio-Stockholders-Reminded-to-Tender-Shares-Before-6-00-PM-New-York-City-Time-on-March-28-2023.html?f=22&fvtc=4&fvtv=15990Chembio Stockholders Reminded to Tender Shares Before 6:00 PM New York City Time, on March 28, 20232023-03-21T11:00:00Z<![CDATA[MEDFORD, N.Y., March 21, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders concerning the pending tender offer by Biosynex SA.]]>https://www.globenewswire.com/news-release/2023/03/15/2627490/0/en/Biosynex-Extends-Tender-Offer-for-the-shares-of-Chembio-Diagnostics-Inc.html?f=22&fvtc=4&fvtv=15990Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.2023-03-15T11:00:00Z<![CDATA[STRASBOURG, France, March 15, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, today announced that Project Merci Merger Sub, Inc. (“Purchaser”), a Nevada corporation and its wholly-owned indirect subsidiary, has extended the expiration time for the previously announced tender offer to purchase all of the issued and outstanding shares of common stock (the “Shares”) of Chembio Diagnostics, Inc. (Nasdaq: CEMI) (“Chembio”) at a price of $0.45 per Share, net to the seller in cash, without interest and subject to any required tax withholding, until 6:00 p.m., New York City time on March 28, 2023, unless further extended. The tender offer was previously scheduled to expire at one minute after 11:59 p.m., New York City time, on March 14, 2023. All other terms and conditions of the tender offer remain unchanged.]]>https://www.globenewswire.com/news-release/2023/03/15/2627485/0/en/Chembio-Announces-Letter-to-Stockholders-Regarding-Tender-Offer.html?f=22&fvtc=4&fvtv=15990Chembio Announces Letter to Stockholders Regarding Tender Offer2023-03-15T11:00:00Z<![CDATA[MEDFORD, N.Y., March 15, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders concerning the pending tender offer by Biosynex SA.]]>https://www.globenewswire.com/news-release/2023/02/24/2615208/0/en/Chembio-Announces-the-Receipt-of-CLIA-Waiver-for-its-DPP-HIV-Syphilis-System.html?f=22&fvtc=4&fvtv=15990Chembio Announces the Receipt of CLIA Waiver for its DPP HIV-Syphilis System2023-02-24T13:00:00Z<![CDATA[MEDFORD, N.Y., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced receipt of a Clinical Laboratory Improvement Amendments (CLIA) waiver from the U.S. Food and Drug Administration (FDA) for the DPP HIV-Syphilis System.]]>